SI2254870T1 - 1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji MCP-1, CX3CR1 - Google Patents

1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji MCP-1, CX3CR1

Info

Publication number: SI2254870T1
Authority: SI; Slovenia
Prior art keywords: cx3cr1; mcp; benzyl; expression; treatment
Prior art date: 2008-03-07

Application number

SI200931404A

Other languages

English (en)

Inventor

Angelo Guglielmotti

Guido Furlotti

Giorgina Mangano

Nicola Cazzolla

Barbara Garofalo

Original Assignee

Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-03-07

Filing date

2009-03-05

Publication date

2016-05-31

2009-03-05 Application filed by Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. filed Critical Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.

2016-05-31 Publication of SI2254870T1 publication Critical patent/SI2254870T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Endocrinology (AREA)
AIDS & HIV (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Transplantation (AREA)

SI200931404A 2008-03-07 2009-03-05 1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji MCP-1, CX3CR1 SI2254870T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP08425139		2008-03-07
PCT/EP2009/052590 WO2009109618A2 (en)	2008-03-07	2009-03-05	Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
EP09718467.5A EP2254870B1 (en)	2008-03-07	2009-03-05	1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1

Publications (1)

Publication Number	Publication Date
SI2254870T1 true SI2254870T1 (sl)	2016-05-31

Family

ID=39671487

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SI200931705T SI2254869T1 (sl)	2008-03-07	2009-03-05	Novi 1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji CX3CR1 in p40
SI200931404A SI2254870T1 (sl)	2008-03-07	2009-03-05	1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji MCP-1, CX3CR1

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SI200931705T SI2254869T1 (sl)	2008-03-07	2009-03-05	Novi 1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji CX3CR1 in p40

Country Status (25)

Country	Link
US (3)	US8835481B2 (sl)
EP (3)	EP3181551A1 (sl)
JP (2)	JP5509099B2 (sl)
KR (2)	KR101581828B1 (sl)
CN (2)	CN101952256B (sl)
AR (2)	AR070811A1 (sl)
AU (2)	AU2009221083B2 (sl)
BR (2)	BRPI0907976A2 (sl)
CA (2)	CA2712403C (sl)
CY (2)	CY1117584T1 (sl)
DK (2)	DK2254869T3 (sl)
EA (2)	EA019711B1 (sl)
ES (2)	ES2569330T3 (sl)
GE (2)	GEP20135983B (sl)
HR (2)	HRP20160462T1 (sl)
HU (1)	HUE027098T2 (sl)
IL (3)	IL206893A0 (sl)
LT (1)	LT2254869T (sl)
MX (2)	MX2010009626A (sl)
PL (2)	PL2254869T3 (sl)
PT (1)	PT2254869T (sl)
SG (1)	SG188177A1 (sl)
SI (2)	SI2254869T1 (sl)
UA (2)	UA103605C2 (sl)
WO (2)	WO2009109613A2 (sl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2753149T3 (es)	2008-03-07	2020-04-07	Acraf	Derivados de 1-bencil-3-hidroximetilindazol y utilización de los mismos en el tratamiento de enfermedades basadas en la expresión de MCP-1, CXCR1 y P40
AR070813A1 (es)	2008-03-07	2010-05-05	Acraf	Nuevos derivados de 1- bencil -3-hidroximetilindazol y su utilizacion en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1
MX2010009626A (es) *	2008-03-07	2010-12-20	Acraf	Derivados de 1-bencil-3-hidroximetilindazol y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1.
PT2462118E (pt) *	2009-08-03	2014-07-25	Acraf	Processo para a preparação de 1-benzil-3-hidroximetil-1 hindazole e derivados do mesmo e intermédios de magnésio requeridos
UA108742C2 (uk)	2009-09-23	2015-06-10		Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
JP2015523546A (ja) *	2012-05-01	2015-08-13	トランスレイタムメディカスインコーポレイテッド	失明性疾患を処置および診断するための方法
US8999292B2 (en) *	2012-05-01	2015-04-07	Translatum Medicus Inc.	Methods for treating and diagnosing blinding eye diseases
SI2882715T1 (sl) *	2012-05-18	2017-03-31	Sanofi	Derivati pirazola in njihova uporaba kot antagonisti LPAR5
EP2850062B1 (en)	2012-05-18	2017-07-19	Sanofi	Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation
WO2014074854A1 (en)	2012-11-09	2014-05-15	Wang Tongxin	Block copolymers for tooth enamel protection
JP6625064B2 (ja) *	2014-05-15	2019-12-25	トランスレイタムメディカスインコーポレイテッド	眼障害を治療かつ診断するための組成物および方法
CN107635404B (zh)	2015-06-12	2021-09-28	威特瑞有限公司	用于治疗疾病的mct4抑制剂
CA2989270A1 (en) *	2015-06-16	2016-12-22	Translatum Medicus, Inc.	Compositions and methods for treating and diagnosing ocular disorders
CN110114351B (zh) *	2016-12-12	2022-09-20	维托尔股份有限公司	Mct4的杂环抑制剂
GB201811169D0 (en)	2018-07-06	2018-08-29	Kancera Ab	New compounds
WO2020026471A1 (ja) *	2018-07-31	2020-02-06	株式会社親広産業	グルコース消費促進剤および解糖系促進剤
JP6612004B1 (ja) *	2018-07-31	2019-11-27	株式会社親広産業	グルコース消費促進剤および解糖系促進剤
EP3990433A4 (en) *	2019-06-25	2023-07-26	Translatum Medicus Inc.	METHODS FOR THE MANUFACTURE OF 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES
CN113929627A (zh) *	2021-10-19	2022-01-14	吕梁学院	一种宾达利的合成方法
WO2024108386A1 (zh) *	2022-11-22	2024-05-30	中国科学院深圳先进技术研究院	抗mcp1中和抗体在制备治疗神经退行性疾病引起的系统性炎症药物中的应用
WO2024165925A1 (en) *	2023-02-10	2024-08-15	Translatum Medicus Inc.	Bindarit conjugates, compositions and methods for treating ocular diseases or disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US364371A (en) *		1887-06-07		peice
US416359A (en) *		1889-12-03		Sash-fastener
IT1230441B (it) *	1989-02-07	1991-10-23	Acraf	Eteri della serie dell'indazolo
IT1253703B (it) *	1991-04-22	1995-08-23	Angelini Francesco Ist Ricerca	Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
IT1293795B1 (it)	1997-07-28	1999-03-10	Angelini Ricerche Spa	Farmaco attivo nel ridurre la produzione di proteina mcp-1
AU781849C (en)	1999-06-17	2006-03-02	Synta Pharmaceuticals Corp.	Inhibitors of IL-12 production
EP1188438A1 (en)	2000-09-15	2002-03-20	Warner-Lambert Company	Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
EP1199074A1 (en)	2000-09-15	2002-04-24	Warner-Lambert Company	Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
ATE417617T1 (de)	2001-03-15	2009-01-15	Seikagaku Kogyo Co Ltd	Mittel zur steurung der expression von il-12
KR100950122B1 (ko)	2001-11-30	2010-03-30	신타 파마슈티칼스 코프.	피리미딘 화합물
AU2004278276B2 (en)	2003-10-07	2007-10-18	Astrazeneca Ab	New 2-substituted, 4-amino-thiazolo(4,5-d) pyrimidines, useful as chemokine receptor antagonists, esp. CX3CR1
ES2641815T3 (es) *	2004-10-29	2017-11-14	Eisai R&D Management Co., Ltd.	Tratamiento para enfermedades inflamatorias
CA2586870A1 (en)	2004-11-10	2006-05-18	Synta Pharmaceuticals Corp.	Il-12 modulatory compounds
CA2587590A1 (en)	2004-11-19	2006-06-08	Synta Pharmaceuticals Corp.	Pyrimidine compounds and uses thereof
AR053347A1 (es)	2005-04-06	2007-05-02	Astrazeneca Ab	Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
UA90707C2 (en)	2005-04-06	2010-05-25	Астразенека Аб	Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
ES2753149T3 (es) *	2008-03-07	2020-04-07	Acraf	Derivados de 1-bencil-3-hidroximetilindazol y utilización de los mismos en el tratamiento de enfermedades basadas en la expresión de MCP-1, CXCR1 y P40
MX2010009626A (es) *	2008-03-07	2010-12-20	Acraf	Derivados de 1-bencil-3-hidroximetilindazol y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1.
AR070813A1 (es) *	2008-03-07	2010-05-05	Acraf	Nuevos derivados de 1- bencil -3-hidroximetilindazol y su utilizacion en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1

2009
- 2009-03-05 MX MX2010009626A patent/MX2010009626A/es active IP Right Grant
- 2009-03-05 GE GEAP200911963A patent/GEP20135983B/en unknown
- 2009-03-05 EP EP17153930.7A patent/EP3181551A1/en not_active Withdrawn
- 2009-03-05 AU AU2009221083A patent/AU2009221083B2/en not_active Ceased
- 2009-03-05 JP JP2010549143A patent/JP5509099B2/ja active Active
- 2009-03-05 CA CA2712403A patent/CA2712403C/en not_active Expired - Fee Related
- 2009-03-05 SI SI200931705T patent/SI2254869T1/sl unknown
- 2009-03-05 KR KR1020107017806A patent/KR101581828B1/ko not_active IP Right Cessation
- 2009-03-05 JP JP2010549146A patent/JP5509101B2/ja active Active
- 2009-03-05 AU AU2009221089A patent/AU2009221089B2/en not_active Ceased
- 2009-03-05 DK DK09717638.2T patent/DK2254869T3/en active
- 2009-03-05 US US12/865,923 patent/US8835481B2/en not_active Expired - Fee Related
- 2009-03-05 PL PL09717638T patent/PL2254869T3/pl unknown
- 2009-03-05 EA EA201071040A patent/EA019711B1/ru not_active IP Right Cessation
- 2009-03-05 PT PT97176382T patent/PT2254869T/pt unknown
- 2009-03-05 DK DK09718467.5T patent/DK2254870T3/en active
- 2009-03-05 CN CN200980105556.4A patent/CN101952256B/zh not_active Expired - Fee Related
- 2009-03-05 WO PCT/EP2009/052585 patent/WO2009109613A2/en active Application Filing
- 2009-03-05 PL PL09718467T patent/PL2254870T3/pl unknown
- 2009-03-05 SG SG2013013123A patent/SG188177A1/en unknown
- 2009-03-05 KR KR1020107017445A patent/KR101599867B1/ko not_active IP Right Cessation
- 2009-03-05 EP EP09718467.5A patent/EP2254870B1/en active Active
- 2009-03-05 US US12/864,767 patent/US7919518B2/en not_active Expired - Fee Related
- 2009-03-05 MX MX2010009623A patent/MX2010009623A/es active IP Right Grant
- 2009-03-05 ES ES09718467.5T patent/ES2569330T3/es active Active
- 2009-03-05 BR BRPI0907976-9A patent/BRPI0907976A2/pt not_active IP Right Cessation
- 2009-03-05 ES ES09717638.2T patent/ES2637009T3/es active Active
- 2009-03-05 GE GEAP200911965A patent/GEP20135912B/en unknown
- 2009-03-05 HU HUE09718467A patent/HUE027098T2/en unknown
- 2009-03-05 CN CN200980105073.4A patent/CN101945855B/zh not_active Expired - Fee Related
- 2009-03-05 EA EA201071038A patent/EA018241B1/ru not_active IP Right Cessation
- 2009-03-05 EP EP09717638.2A patent/EP2254869B1/en active Active
- 2009-03-05 LT LTEP09717638.2T patent/LT2254869T/lt unknown
- 2009-03-05 WO PCT/EP2009/052590 patent/WO2009109618A2/en active Application Filing
- 2009-03-05 CA CA2712703A patent/CA2712703C/en not_active Expired - Fee Related
- 2009-03-05 SI SI200931404A patent/SI2254870T1/sl unknown
- 2009-03-05 BR BRPI0907977-7A patent/BRPI0907977A2/pt not_active IP Right Cessation
- 2009-03-06 AR ARP090100801A patent/AR070811A1/es unknown
- 2009-03-06 AR ARP090100800A patent/AR070810A1/es unknown
- 2009-05-03 UA UAA201008883A patent/UA103605C2/uk unknown
- 2009-05-03 UA UAA201008570A patent/UA105170C2/uk unknown
2010
- 2010-07-08 IL IL206893A patent/IL206893A0/en not_active IP Right Cessation
- 2010-07-21 IL IL207131A patent/IL207131A/en not_active IP Right Cessation
2011
- 2011-03-07 US US13/041,557 patent/US8283348B2/en not_active Expired - Fee Related
- 2011-10-06 IL IL215579A patent/IL215579A/en not_active IP Right Cessation
2016
- 2016-05-02 HR HRP20160462TT patent/HRP20160462T1/hr unknown
- 2016-05-13 CY CY20161100406T patent/CY1117584T1/el unknown
2017
- 2017-08-07 HR HRP20171208TT patent/HRP20171208T1/hr unknown
- 2017-08-09 CY CY20171100858T patent/CY1119252T1/el unknown

Also Published As

Publication number	Publication date
EA201071038A1 (ru)	2011-02-28
IL215579A0 (en)	2011-11-30
AU2009221089B2 (en)	2013-12-05
PL2254870T3 (pl)	2016-07-29
HRP20171208T1 (hr)	2017-10-06
CN101952256A (zh)	2011-01-19
US8835481B2 (en)	2014-09-16
GEP20135912B (en)	2013-08-26
IL215579A (en)	2015-06-30
GEP20135983B (en)	2013-12-10
CY1119252T1 (el)	2018-02-14
US8283348B2 (en)	2012-10-09
JP5509101B2 (ja)	2014-06-04
AR070811A1 (es)	2010-05-05
AU2009221089A1 (en)	2009-09-11
HUE027098T2 (en)	2016-08-29
PT2254869T (pt)	2017-07-18
EP2254870B1 (en)	2016-02-24
WO2009109613A2 (en)	2009-09-11
BRPI0907977A2 (pt)	2015-08-04
IL206893A0 (en)	2010-12-30
UA105170C2 (en)	2014-04-25
WO2009109618A2 (en)	2009-09-11
EP2254869A2 (en)	2010-12-01
AU2009221083B2 (en)	2013-11-28
KR101599867B1 (ko)	2016-03-04
MX2010009626A (es)	2010-12-20
KR20100131432A (ko)	2010-12-15
ES2569330T3 (es)	2016-05-10
IL207131A0 (en)	2010-12-30
EP2254870A2 (en)	2010-12-01
ES2637009T3 (es)	2017-10-10
DK2254870T3 (en)	2016-05-17
US20100311744A1 (en)	2010-12-09
EA201071040A1 (ru)	2011-02-28
UA103605C2 (en)	2013-11-11
EP2254869B1 (en)	2017-05-31
JP5509099B2 (ja)	2014-06-04
HRP20160462T1 (hr)	2016-06-03
BRPI0907976A2 (pt)	2015-08-04
EA019711B1 (ru)	2014-05-30
CN101945855A (zh)	2011-01-12
SG188177A1 (en)	2013-03-28
CA2712403A1 (en)	2009-09-11
DK2254869T3 (en)	2017-09-04
KR101581828B1 (ko)	2015-12-31
US20110003874A1 (en)	2011-01-06
AR070810A1 (es)	2010-05-05
US20110160205A1 (en)	2011-06-30
EA018241B1 (ru)	2013-06-28
CA2712703C (en)	2016-10-11
IL207131A (en)	2013-02-28
AU2009221083A1 (en)	2009-09-11
JP2011513365A (ja)	2011-04-28
CY1117584T1 (el)	2017-04-26
SI2254869T1 (sl)	2017-10-30
EP3181551A1 (en)	2017-06-21
PL2254869T3 (pl)	2017-10-31
LT2254869T (lt)	2017-08-10
CA2712703A1 (en)	2009-09-11
CN101952256B (zh)	2016-03-16
MX2010009623A (es)	2010-09-28
CA2712403C (en)	2017-06-06
KR20100133957A (ko)	2010-12-22
US7919518B2 (en)	2011-04-05
WO2009109618A3 (en)	2009-12-10
JP2011513367A (ja)	2011-04-28
WO2009109613A3 (en)	2009-12-10
CN101945855B (zh)	2014-12-17

Publication	Publication Date	Title
HRP20191953T8 (hr)	2021-06-25	DERIVATI 1-BENZIL-3-HIDROKSIMETILINDAZOLA I NJIHOVA UPORABA U LIJEČENJU BOLESTI KOJE SE BAZIRAJU NA EKSPRESIJI MCP-1, CX3CR1 i P40
SI2254870T1 (sl)	2016-05-31	1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji MCP-1, CX3CR1
IL207278A0 (en)	2010-12-30	1 - benzyl - 3 - hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp - 1, and cx3cr1
HK1253532A1 (zh)	2019-06-21	用於治療變應性、炎性和感染性疾病的嘌呤衍生物
IL210803A0 (en)	2011-04-28	Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
HK1170485A1 (zh)	2013-03-01	-噻唑烷- -酮衍生物及其在癌症治療中的用途
IL216967B (en)	2018-06-28	The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
SI2148667T1 (sl)	2013-12-31	Uporaba derivatov cikloheksanheksola pri zdravljenju okularnih bolezni
HK1168283A1 (zh)	2012-12-28	類的試劑在治療抗胰島素和相關疾病的用途
IL217300A0 (en)	2012-02-29	Pyrazole derivatives' prepartion thereof, and therapeutic use thereof
TH0901005786A (th)	2016-04-07	อนุพันธ์พิวรีนเพื่อใช้ในการรักษาโรคภูมิแพ้, อาการอักเสบ และโรคติดเชื้อ